Sucampo Pharmaceuticals (NASDAQ:SCMP) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Tuesday.

Several other research analysts have also issued reports on the stock. ValuEngine upgraded shares of Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, December 1st. began coverage on shares of Sucampo Pharmaceuticals in a research report on Wednesday, November 15th. They issued a “buy” rating and a $14.00 target price for the company. B. Riley began coverage on shares of Sucampo Pharmaceuticals in a research report on Tuesday, November 14th. They set a “buy” rating and a $14.00 price target for the company. Maxim Group restated a “buy” rating and set a $23.00 price target on shares of Sucampo Pharmaceuticals in a research report on Thursday, November 2nd. Finally, Mizuho restated a “hold” rating and set a $12.00 price target on shares of Sucampo Pharmaceuticals in a research report on Wednesday, November 1st. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $16.60.

Shares of Sucampo Pharmaceuticals (NASDAQ SCMP) traded up $0.40 during trading hours on Tuesday, reaching $16.00. Sucampo Pharmaceuticals has a fifty-two week low of $9.30 and a fifty-two week high of $17.70. The company has a market capitalization of $746.19, a P/E ratio of 10.96, a P/E/G ratio of 4.76 and a beta of 1.47. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The company had revenue of $61.27 million during the quarter, compared to analyst estimates of $58.05 million. During the same period in the previous year, the business earned $0.30 earnings per share. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. equities analysts anticipate that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current fiscal year.

In other Sucampo Pharmaceuticals news, major shareholder Sachiko Kuno sold 1,000,000 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $12.00, for a total transaction of $12,000,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.13% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of SCMP. Point72 Asset Management L.P. purchased a new stake in shares of Sucampo Pharmaceuticals during the third quarter worth about $21,989,000. Rubric Capital Management LP purchased a new stake in shares of Sucampo Pharmaceuticals during the second quarter worth about $6,068,000. Vanguard Group Inc. boosted its holdings in shares of Sucampo Pharmaceuticals by 48.9% during the first quarter. Vanguard Group Inc. now owns 1,456,787 shares of the biopharmaceutical company’s stock worth $16,024,000 after purchasing an additional 478,226 shares during the period. Prudential Financial Inc. boosted its holdings in shares of Sucampo Pharmaceuticals by 871.6% during the third quarter. Prudential Financial Inc. now owns 410,323 shares of the biopharmaceutical company’s stock worth $4,842,000 after purchasing an additional 368,090 shares during the period. Finally, Systematic Financial Management LP purchased a new stake in shares of Sucampo Pharmaceuticals during the second quarter worth about $1,648,000. Institutional investors and hedge funds own 65.31% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Sucampo Pharmaceuticals (SCMP) Raised to “Buy” at BidaskClub” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/10/sucampo-pharmaceuticals-scmp-raised-to-buy-at-bidaskclub.html.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.